Legal & General Group
RLMD icon

Legal & General Group’s Relmada Therapeutics RLMD Stock Holding History

Legal & General Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.5K Buy
+9,181
New +$64.2K ﹤0.01% 2706
2023
Q2 		– Sell
-3,074
Closed -$6.95K – 3500
2023
Q1 		$6.95K Hold
3,074
– – ﹤0.01% 3260
2022
Q4 		$10.7K Sell
3,074
-5,829
-65% -$51.2K ﹤0.01% 3257
2022
Q3 		$329K Buy
8,903
+1,224
+16% +$33.9K ﹤0.01% 2456
2022
Q2 		$145K Sell
7,679
-122
-2% -$2.66K ﹤0.01% 2750
2022
Q1 		$211K Buy
7,801
+1,033
+15% +$21.4K ﹤0.01% 2649
2021
Q4 		$153K Buy
6,768
+2,377
+54% +$52.9K ﹤0.01% 2807
2021
Q3 		$115K Buy
4,391
+2,231
+103% +$59.7K ﹤0.01% 2814
2021
Q2 		$69K Hold
2,160
– – ﹤0.01% 2854
2021
Q1 		$76K Sell
2,160
-92
-4% -$3.22K ﹤0.01% 2697
2020
Q4 		$72K Hold
2,252
– – ﹤0.01% 2685
2020
Q3 		$84K Sell
2,252
-583
-21% -$22.5K ﹤0.01% 2535
2020
Q2 		$127K Buy
+2,835
New +$120K ﹤0.01% 2469

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Legal & General Group's RLMD Position: Q2 2026 in Review

Legal & General Group opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 9,181 shares worth $63.5K. The stake represents ﹤0.01% of the portfolio and ranks #2706 among its holdings. This is a return to the name: Legal & General Group previously reported a position in RLMD as recently as Q1 2023.

Legal & General Group first reported a position in RLMD in Q2 2020 and has held it in 13 quarters since. The position peaked at $329K in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Legal & General Group held 9,181 shares of Relmada Therapeutics worth $63.5K as of Q2 2026.
  • Relmada Therapeutics was a new Legal & General Group position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2706 holding.
  • Legal & General Group first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Legal & General Group's Relmada Therapeutics position peaked at $329K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.